2020-06-13T02:14:12Zhttps:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi
oai:pubmedcentral.nih.gov:23942302009-09-10brjcancerpmc-open
Br J Cancer British Journal of Cancer 0007-0920 1532-1827 Nature Publishing Group PMC2394230 PMC2394230 2394230 12838319 6600983 10.1038/sj.bjc.6600983 12838319 Experimental Therapeutics Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines Fustier P 1 Le Corre L 1 Chalabi N 1 Vissac-Sabatier C 1 Communal Y 2 Bignon Y-J 1 * Bernard-Gallon D J 1 1Laboratoire d'Oncologie Moléculaire, Centre Jean Perrin, 58 Rue Montalembert, BP 392, 63011 Clermont-Ferrand, France 2Laboratoire d'Immunologie, Centre Jean Perrin, 58 Rue Montalembert, BP 392, 63011 Clermont-Ferrand, France Author for correspondence: Yves-Jean.Bignon@cjp.u-clermont1.fr 01 07 2003 07 07 2003 89 1 168 172 09 12 2002 17 03 2003 19 03 2003 Copyright 2003, Cancer Research UK 2003 Cancer Research UK

Resveratrol is a natural phytoalexin compound found in grapes and other food products. It has been found to possess oncopreventive activity by inhibiting ribonucleotide reductase (Fontecave et al, 1998) and cellular events associated with cell proliferation and tumour initiation, promotion and progression (Jang et al, 1997; Mgbonyebi et al, 1998). Resveratrol is a phyto-oestrogen, binding to and activating the oestrogen receptors that regulate the transcription of oestrogen-responsive target genes (Gehm et al, 1997) by either binding directly to DNA, at oestrogen response element (EREs), or by interacting with other transcription factors, for example, Sp1 (Sun et al, 1998), bound to their cognate sites on DNA (Bowers et al, 2000). Others have shown that steady-state BRCA1 mRNA levels are elevated in response to oestrogens in human breast cancer cells, and that BRCA2 expression is also regulated by oestrogens in human breast cancer cell lines (Gudas et al, 1995; Spillman and Bowcock, 1996).

BRCA1 and BRCA2 are breast cancer susceptibility genes: inheritance of one defective copy of either of the two genes predisposes individuals to breast, ovarian and other cancers. The contribution of these genes to the pathogenesis of breast cancer is still unclear. No sporadic breast tumours have been shown to harbour mutations in the coding sequence of BRCA1 or BRCA2 (Miki et al, 1994; Foster et al, 1996). In contrast to normal breast epithelial cells, BRCA1 mRNA levels in tumours appeared to be downregulated by methylation (Dobrovic and Simpfendorfer, 1997), while BRCA2 showed significant overexpression in sporadic breast cancers (Bieche and Lidereau, 1999).

Here, we studied the effects of resveratrol on the expression of BRCA1 and BRCA2 in human breast cancer cell lines at the transcription level using quantitative real-time reverse transcription (RT)–PCR, and at the translation level by perfusion chromatography of the proteins.

MATERIALS AND METHODS Cell cultures

MCF7 (Soule et al, 1973), MDA-MB 231 (Cailleau et al, 1974) and HBL 100 (Ziche and Gullino, 1982) cell lines were purchased from the ATCC (American Type Culture Collection, Manassas, VA, USA). Cells were cultured, respectively, in RPMI 1640, Leibovitz's L15 and McCoy's 5a medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 2 mM L-glutamine, 20 μg ml−1 gentamycin and 10% heat-inactivated FBS. Cells were grown in a humidified incubator with 5% carbon dioxide (except for MDA-MB 231 without CO2) at 37°C. Insulin (0.04 U ml−1) was added for MCF7 culture medium.

The ER status was checked in cell lines by immunocytochemistry with Centre Jean Perrin's anatomopathologist. MCF7 were found ER α+/β+, HBL 100 ER α−/β+ and MDA-MB-231 ER α−/β+.

 Resveratrol treatment of cells and flow cytometry analysis

MCF7, MDA-MB 231 and HBL 100 cells were maintained in medium supplemented with 10, 30 or 50 μm trans-resveratrol (Sigma Chimie, St Quentin Fallavier, France) in DMSO for treated cells. A cell control was performed with DMSO. Cells were collected after 24, 48 or 72 h by trypsinisation and the DNA content was assessed by flow cytometry according to Krishan's (1975) method. Each experiment was performed in triplicate.

 Radiolabelling of cellular proteins

For cellular protein labelling, the cells were fed with 5 ml of medium supplemented with 100 μCi [35S] methionine (1000 Ci mM−1; Amersham International, Bucks, UK) and incubated for 20 h at 37°C in a 5% CO2 atmosphere. Metabolic radiolabelling was stopped by adding 10 ml cold PBS and cells were gently washed twice with PBS at 4°C. Labelled cells were solubilised in 750 μl of 0.1 M Tris-HCl pH 7.1 containing 0.5% Nonidet P40 (NP 40; Boehringer Mannheim, Germany), sonicated for 2 min in ice and incubated at 4°C for 30 min. The insoluble material was removed by ultracentrifugation at 30 000 g for 30 min.

 Purification of DNA-binding proteins by affinity chromatography

The NP 40 cell lysates were loaded onto a POROS 20 HE (heparin) media column (PerSeptive Biosystems, Framingham, MA, USA). Proteins specifically bound to the gel were eluted with a gradient of NaCl from 0.1 to 1 M in 20 mM MES pH 5.5. The flow rate was 5 ml min−1 with a BioCAD Sprint high-performance liquid chromatography system (PerSeptive Biosystems, Framingham, MA, USA) equipped with a fraction collector (Gilson, Middleton, WI, USA). Fractions (0.5 ml) containing DNA-binding proteins were collected and pooled. Radioactivity was measured by adding 10 μl of the collected fractions to 5 ml of scintillation cocktail (Packard Ready Safe) and counting.

 Isolation of <italic>BRCA1</italic> and <italic>BRCA2</italic> by affinity chromatography

BRCA1 or BRCA2 were immunoprecipitated from the previous eluate by addition of 16 μg anti-BRCA1 polyclonal antibodies (556445; GeneTex, San Antonio, TX, USA) or anti-BRCA2 polyclonal antibodies (C-19; Santa Cruz Biotechnology) with a 30-min incubation at 37°C. The immunoprecipitate was isolated after fixation on POROS A column (PerSeptive Biosystems, Framingham, MA, USA) containing Protein A media and eluted 12 mM HCl/0.15 M NaCl, pH 2. Radioactivity of each 1 ml fraction was measured as described previously.

Immune complex elution from the Protein A column gave the amount of DNA-binding proteins that bound to anti-BRCA1 or anti-BRCA2 polyclonal antibodies, and a ratio was calculated as follows: 100 × (d.p.m. of BRCA1 or BRCA2 eluted from Protein A/d.p.m. of total DNA-binding proteins eluted from the heparin column). All data were expressed as means±s.d. of three assays (Hizel et al, 1999; Vissac et al, 2001).

 RNA extraction and cDNA synthesis

Total RNA was isolated using TRIZOL® (Gibco BRL, Carlsbad, CA, USA) according to the manufacturer's protocol. Total RNA (1 μg) was used for the synthesis of first strand cDNA using the First Strand cDNA Synthesis kit (Amersham Pharmacia Biotech, Uppsala, Sweden) following the manufacturer's instructions.

 Determination of <italic>BRCA1</italic> and <italic>BRCA2</italic> mRNA using real-time quantitative RT–PCR

For BRCA1 and BRCA2 expression analysis, probes and primers were designed so that they overlapped splice junction, thereby avoiding the potential amplification of genomic DNA. The sequence of forward primers, TaqMan® probes and reverse primers were, respectively, for BRCA1-exons (ex) 23/24 amplification: 5′-5566CAGAGGACAATGGCTTCCATG5586-3′, 5′-5588AATTGGGCA GATGTGTGAGGCACCTG5613-3′, 5′-5646CTACACTGTCCAACACCCACTCTC5623-3′; for BRCA1-ex 11/12 amplification: 5′-4157AAGAGGAACGGGCTTGGAA4175-3′, 5′-4177AAAATAATCAAGAAGAGCAAAGCATGGATTCAAACTTA4214-3′, 5′-4236CACACCCAGATGCTGCTTCA4217-3′; for BRCA2-ex 26/27 amplification: 5′-9794CCAAGTGGTCCACCCCAAC9812-3′, 5′-9818ACTGTACTTCAGGGCCGTACACTGCTCAAA9847-3′, 5′-9895CACAATTAGGAGAAGACATCAGAAGC9870-3′; for BRCA2-ex 12/13 amplification: 5′-7120GAAAATCAAGAAAAATCCTTAAAGGCT7147-3′, 5′-7153AGCACTCCAGATGGCACAATAAAAGATCGAAG7184-3′,5′-7220GTAATCGGCTCTAAAGAAACATGATG7195-3′. All doubly labelled probes, 18 S rRNA probe, primers plus TaqMan universal PCR master Mix were obtained from Applied Biosystems.

Multiplex PCR was carried out in 96-well plates on cDNA. A typical 25 μl reaction sample contained 12.5 μl TaqMan universel PCR Master Mix (dATP, dCTP, dGTP and dUTP, MgCl2, AmpliTaqGold, Amperase uracil-N-glycolsylase (UNG)), 200 nM of chosen BRCA1 or BRCA2 primers and TaqMan® probes, 50 nM of 18S rRNA primers and TaqMan® probe. Thermal cycling conditions were 2 min at 50°C and 10 min at 95°C followed with 40 cycles at 95°C for 15 s and 60°C for 1 min. Data were collected using the ABI PRISM 7700 SDS analytical thermal cycler (Applied Biosystems, Foster City, CA, USA).

Relative gene expression was determined using the comparative CT (threshold cycle) method, which consists of the normalisation of the number of target gene copies to an endogenous reference gene (18S rRNA), designated as the calibrator (Fink et al, 1998). The level of BRCA1-ex 23/24, BRCA1-ex 11/12, BRCA2-ex 12/13 or BRCA2-ex 26/27 mRNA expression in each treated cell line was then normalised to the result obtained in the untreated cells. The amount of target, normalised to the 18S rRNA endogenous reference is given by the formula: 2−ΔΔCT. To guarantee the reproducibility of mRNA determination, two independent total RNA extractions were performed. Two independent RTs were carried out for one RNA extraction, while only one was performed for the second extraction. Each RT was analysed in triplicate and expressed as a mean±s.d. (Favy et al, 2000).

 RESULTS Cell proliferation by DNA content analysis

Treatments with 10, 30 and 50 μM resveratrol were studied by flow cytometry after different times of exposure (24, 48 and 72 h) in MCF7, MDA-MB 231 and HBL 100 breast tumour cell lines. After exposure, all three cell lines were blocked in S phase. At 48 h, the percentage of cells in S phase was considerably increased after treatment with 30 μM resveratrol, whereas the percentage of cells in G1 phase was decreased. It is well known that resveratrol treatment causes an accumulation of cells in S phase (Ragione et al, 1998).

 Analysis of the impact of resveratrol on <italic>BRCA1</italic> and <italic>BRCA2</italic> mRNA level

We compared the levels of BRCA1 mRNA after treatment with 30 μM resveratrol using two different BRCA1 Taqman probes. The probe, BRCA1-ex 23/24, was used to quantify all BRCA1 mRNA species together because no alternative splicing of ex 23 has been described (Wilson et al, 1997). The BRCA1-ex 11/12 probe was used to estimate the level of mRNA containing ex 11, because Thakur et al (1997) described the isolation and expression of two BRCA1 cDNAs, one of them is a splicing variant generated by exclusion of ex 11 and producing a 4.6 kb mRNA. They observed a complex tissue-specific pattern of multiple spliced forms of BRCA1, and suggested that splicing may play a role in the regulation of BRCA1 function.

To evaluate BRCA2 expression, we designed a TaqMan probe bridging exs 26–27, BRCA2-ex 26/27, because no alternative splicing has been observed so far, at this site. The BRCA2-ex 12/13 probe was used to estimate the level of mRNA containing ex 12, because Bièche and Lidereau (1999) identified an alternatively spliced BRCA2 transcript that was widely expressed in all normal tissues examined. This Δ12-BRCA2 transcript was found to be overexpressed in steroid receptor-negative breast tumour tissues, suggesting that dysregulation of the Δ12-BRCA2 isoform may contribute to progression in human breast cancer.

Expression of BRCA1 and BRCA2 mRNA in resveratrol-treated cells was normalised to their expression levels in untreated cells, normalised to 1. As shown in Figure 1

Effect of resveratrol on BRCA1-ex 23/24 (A) and BRCA1-ex 11/12 (B) mRNA levels in MCF7, MDA-MB 231 and HBL 100 after 48 h of treatment. Expression in treated cells was normalised to untreated controls (corresponding to arbitrary value: 1). Each measure was performed on two extractions and three RT and is expressed as mean±s.d. Statistic analysis was performed using the Student's t-test (*: P<0.05).

, the expression of each BRCA1 mRNA species (BRCA1-ex 23/24 and BRCA1-ex 11/12) was increased in all three cell lines after treatment.

We also observed an increase of BRCA2-ex 26/27 and BRCA2-ex 12/13 mRNA in all three cell lines (Figure 2

Effect of resveratrol on BRCA2-ex 26/27 (A) and BRCA2-ex 12/13 (B) mRNA levels in MCF7, MDA-MB 231 and HBL 100 after 48 h of treatment. Expression in treated cells was normalised to untreated controls (corresponding to arbitrary value: 1). Each measure was performed on two extractions and three RT and is expressed as mean±s.d. Statistic analysis was performed using the Student's t-test (*: P<0.05).

). All mRNA determinations with treated cells were expressed as mean±s.d., with a student's t-test.

 Analysis of the impact of resveratrol on <italic>BRCA1</italic> and <italic>BRCA2</italic> protein synthesis

The amount of BRCA1 or BRCA2 protein was expressed as the following ratio: d.p.m. of labelled DNA-binding proteins bound specifically by the antibodies to BRCA1 or BRCA2/d.p.m. of total DNA-binding proteins purified by heparin chromatography (Table 1

Amount of BRCA1 and BRCA2 proteins expressed by MCF-7, MDA-MB 231 and HBL 100 cells after treatment with 30 μM resveratrol and 48 h exposure.

  Proteins assayed (%)
 Cell linesBRCA1BRCA2
MCF-7Untreated controls0.58±0.011.00±0.03
 30 μM resveratrol0.51±0.02*0.80±0.16*
MDA-MB231Untreated controls1.85±0.340.48±0.12
 30 μM resveratrol1.80±0.320.41±0.02
HBL100Untreated controls0.95±0.040.90±0.09
 30 μM resveratrol1.15±0.181.00±0.03
). BRCA1 and BRCA2 protein expression was not modified 48 h after treatment with 30 μM resveratrol.

 DISCUSSION

We studied the effect of resveratrol, a natural polyphenolic compound found especially in black grapes, peanuts, berries and Itadori tea (Burns et al, 2002), on the expression of the BRCA1 and BRCA2 genes in the human breast cancer cell lines MCF7, MDA-MB 231 and HBL 100. We chose 48 h exposure to 30 μM resveratrol because this treatment was shown to increase significantly the number of cells blocked in S phase (Park et al, 2001). It is well known that BRCA1 and BRCA2 reach their maximal levels in late G1 and S phases in normal and tumour-derived breast epithelial cells (Vaughn et al, 1996; Bertwistle et al, 1997).

Moreover, the effects of 30 μM resveratrol correlated with results from others also studying resveratrol in cell lines (Ragione et al, 1998; Hsieh et al, 1999; Igura et al, 2001). In addition, we used a lower dose of 10 μM resveratrol in the three cell lines (data not shown), but that did not show any accumulation of cells in S phase and consequently no significant alteration was found for BRCA1, BRCA2 mRNA and BRCA1, BRCA2 proteins.

Then, the quantification of BRCA1 and BRCA2 mRNA was performed with real-time quantitative RT–PCR. This method allowed us to compare the effect of resveratrol by comparison with untreated cells, which were normalised to one. In MCF7, BRCA1 mRNA increased 2.5-fold and BRCA2 mRNA four-fold after 48 h in the presence of 30 μM resveratrol. Similarly, in MDA-MB 231, BRCA1 mRNA increased three-fold and BRCA2 mRNA two-fold while in HBL 100, BRCA1 mRNA increased 2.6-fold and BRCA2 mRNA 1.9-fold.

The effect of resveratrol on BRCA1 and BRCA2 mRNA in human breast cancer cell lines could be explained by its different properties. First, it is structurally similar to the synthetic oestrogen, diethylstilbestrol, which exhibits oestrogenic activity. Gehm et al (1997) reported that resveratrol inhibited the binding of labelled oestradiol to the oestrogen receptor and activated transcription of oestrogen-responsive reporter genes transfected into human breast cancer cells. This transcriptional activation was oestrogen receptor-dependent, required an ERE in the reporter gene, and was inhibited by specific oestrogen antagonists. Moreover, resveratrol showed oestrogen agonist activity in MCF7 cells by activating the expression of two oestrogen-responsive genes, such as progesterone receptor (PR) and pS2 genes (Jang and Pezzuto, 1999). And, we also found elsewhere an increase in pS2 mRNA in MCF7, HBL100 and MDA-MB-231 human breast cancer cell lines (unpublished data). Resveratrol binds ER β and ER α with comparable affinity. However, resveratrol-liganded ER β has higher transcriptional activity than 17β-oestradiol-liganded ER β. This indicates that the cells that uniquely express ER β or that express higher levels of ER β than ER α may be more sensitive to resveratrol's oestrogen agonist activity (Bowers et al, 2000). Furthermore, the oestrogen agonist activity of resveratrol depends on the ERE sequence and the type of ER. Thus, in some cell types (e.g., MCF7 cells), resveratrol functioned as a superagonist (i.e., produced a greater maximal transcriptional response than oestradiol), whereas in others it produced activation equal to or less than that of oestradiol (Gehm et al, 1997). On the other hand, an ERE has been described in the promoter of BRCA1 (Xu et al, 1997). This can explain the fold increases in BRCA1 and BRCA2 mRNA across the different cell types.

The steady-state levels of BRCA1 and BRCA2 mRNAs were shown to be coordinately elevated by oestrogen in human breast cancer cell lines MCF7 and BT 483 (Spillman and Bowcock, 1996). Elsewhere, the expression of BRCA1 mRNA was induced from 2.5- to 5.0-fold by oestrogen in human breast cancer cell lines MCF7, and the BRCA1 protein was about three-fold (Romagnolo et al, 1998). In our work, we found a comparable increase, of two- to four-fold for BRCA1 and BRCA2 mRNA, by resveratrol in human breast cell lines MCF7, MDA-MB 231 and HBL 100. The ER status for MCF7 were found ER α+/β+, HBL 100 (ER α–/β+) and MDA-MB 231 (ER α–/ER β+).

BRCA1 and BRCA2 proteins were quantified using two successive perfusion affinity chromatographies. Resveratrol had no effect on the level of either BRCA1 or BRCA2. We displayed the specificity of the anti-BRCA1 and anti-BRCA2 polyclonal antibodies by competition with the synthetic peptides used to generate the antibodies. A complete displacement of the equilibrium was obtained in each case demonstrating the specificity of the antibodies (data not shown) (Hizel et al, 1999; Vissac et al, 2001, 2002).

We found an increase in BRCA1 and BRCA2 mRNA after treatment with resveratrol in breast cancer cell lines but no effect at the protein level. These result suggest an uncoupling between mRNA and protein levels under these conditions. A similar uncoupling of BRCA1 mRNA and protein levels was detected in synchronised populations of immortalised MCF10 and 184B5 cells proliferation. In these two cell lines, BRCA1 mRNA level was tightly regulated during the cell cycle while BRCA1 protein level remained constant. Thus, it has been shown that BRCA1 mRNA is highly expressed in late G1 phase of the cell cycle, whereas conditions that lead to cell cycle exit downregulate the BRCA1 mRNA (Gudas et al, 1995, 1996; Jin et al, 1997). There are several possible explanations for discrepancies between mRNA and protein level under different physiological conditions. BRCA1 and BRCA2 might be post-transcriptionally regulated with effects on the translational activity as well as the stability of BRCA1 and BRCA2 mRNA (Wickens et al, 1997). Alternatively, the level of BRCA1 mRNA in cells may be translationally regulated by other cellular proteins or antisense RNA transcripts. Precedents for both mechanisms of regulation exist for other genes. Interestingly, many developmentally regulated genes exhibit regulation at the level of mRNA translation (Hentze, 1995). More recently, Blagosklonny et al (1999) demonstrated a substantial role for proteolysis in regulating BRCA1 steady-state protein levels in several cell lines. Degradation by a cathepsin-like protease in fine balance with BRCA1 transcription is responsible for maintaining the low steady-state level of BRCA1 protein seen in many cancer cells. At the opposite of oestrogen, which increased the level of mRNAs and proteins of the two oncosuppressors BRCA1 and BRCA2, the resveratrol seems to play a role in one of the different pathways of previous mechanisms.

To better understand the effects of resveratrol on BRCA1 and BRCA2 oncosuppressor genes in mammary gland, we will use cDNA microarrays to study gene-expression profiles of proteins interacting with BRCA1 and BRCA2 after phytochemical treatment and it would be helpful to study proteomics.

In conclusion, the present study demonstrates that 30 μM resveratrol can increase expression of the BRCA1 and BRCA2 oncosuppressors, involved in the aggressiveness of human breast cancer cell lines.

The grant sponsors are L'Association de la Recherche contre le Cancer, Villejuif, France, La Ligue Nationale Française de Lutte Contre le Cancer and Le Comité du Puy-de-Dôme. Ludovic Le Corre and Cécile Vissac-Sabatier are recipients of a grant from the MENRT (Ministère de l'Education Nationale, de la Recherche et de la Technologie).

 Bertwistle D Swift S Marston NJ Jackson LE Crossland S Crompton MR Marshall CJ Ashworth A Nuclear location and cell cycle regulation of the BRCA2 protein Cancer Res 1997 57 5485 5488 9407955 Bieche I Lidereau R Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumour breast tissue compared with normal tissue Cancer Res 1999 59 2546 2550 10363970 Blagosklonny MV An WG Melillo G Nguyen P Trepel JB Neckers LM Regulation of BRCA1 by protein degradation Oncogene 1999 18 6460 6468 10597248 Bowers JL Tyulmenkov VV Jernigan SC Klinge CM Resveratrol acts as a mixed agonist/antagonist for oestrogen receptors alpha and beta Endocrinology 2000 141 3657 3667 11014220 Burns J Yokota T Ashihara H Lean ME Crozier A Plant foods and herbal sources of resveratrol J Agric Food Chem 2002 50 3337 3340 12010007 Cailleau R Mackay B Young RK Reeves WJ Jr Tissue culture studies on pleural effusions from breast carcinoma patients Cancer Res 1974 34 801 809 4592574 Dobrovic A Simpfendorfer D Methylation of the BRCA1 gene in sporadic breast cancer Cancer Res 1997 57 3347 3350 9269993 Favy DA Lafarge S Rio P Vissac C Bignon YJ Bernard-Gallon D Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines Biochem Biophys Res Commun 2000 274 73 78 10903898 Fink L Seeger W Ermert L Hanze J Stahl U Grimminger F Kummer W Bohle RM Real-time quantitative RT–PCR after laser-assisted cell picking Nat Med 1998 4 1329 1333 9809560 Fontecave M Lepoivre M Elleingand E Gerez C Guittet O Resveratrol, a remarkable inhibitor of ribonucleotide reductase FEBS Lett 1998 421 277 279 9468322 Foster KA Harrington P Kerr J Russell P DiCioccio RA Scott IV Jacobs I Chenevix-Trench G Ponder BA Gayther SA Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer Cancer Res 1996 56 3622 3625 8705994 Gehm BD McAndrews JM Chien PY Jameson JL Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the oestrogen receptor Proc Natl Acad Sci USA 1997 94 14138 14143 Gudas JM Li T Nguyen H Jensen D Rauscher FJ III Cowan KH Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells Cell Growth Differ 1996 7 717 723 8780885 Gudas JM Nguyen H Li T Cowan KH Hormone-dependent regulation of BRCA1 in human breast cancer cells Cancer Res 1995 55 4561 4565 7553629 Hentze MW Translational regulation: versatile mechanisms for metabolic and developmental control Curr Opin Cell Biol 1995 7 393 398 7662370 Hizel C Maurizis JC Rio P Communal Y Chassagne J Favy D Bignon YJ Bernard-Gallon DJ Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography J Chromatogr B Biomed Sci Appl 1999 721 163 170 10052688 Hsieh TC Juan G Darzynkiewicz Z Wu JM Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2 Cancer Res 1999 59 2596 2601 10363980 Igura K Ohta T Kuroda Y Kaji K Resveratrol and quercetin inhibit angiogenesis in vitro Cancer Lett 2001 171 11 16 11485823 Jang M Cai L Udeani GO Slowing KV Thomas CF Beecher CW Fong HH Farnsworth NR Kinghorn AD Mehta RG Moon RC Pezzuto JM Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 1997 275 218 220 8985016 Jang M Pezzuto JM Cancer chemopreventive activity of resveratrol Drugs Exp Clin Res 1999 25 65 77 10370867 Jin Y Xu XL Yang MC Wei F Ayi TC Bowcock AM Baer R Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains Proc Natl Acad Sci USA 1997 94 12075 12080 Krishan A Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining J Cell Biol 1975 66 188 193 49354 Mgbonyebi OP Russo J Russo IH Antiproliferative effect of synthetic resveratrol on human breast epithelial cells Int J Oncol 1998 12 865 869 9499448 Miki Y Swensen J Shattuck-Eidens D Futreal PA Harshman K Tavtigian S Liu Q Cochran C Bennett LM Ding W Bell R Rosenthal J Hussey C Tran T McClure M Frye C Hattier T Phelps R Haugen-Strano A Katcher H Yakumo K Gholami Z Shaffer D Stone S Bayer S Wray C Bogden R Dayananth P Ward J Tonin P Narod S Bristow PK Norris FH Helvering L Morrison P Rosteck P Lai M Barrett JC Lewis C Neuhausen S Cannon-Albright L Goldgar D Wiseman R Kamb A Skolnick MH A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 1994 266 66 71 7545954 Park JW Choi YJ Jang MA Lee YS Jun DY Suh SI Baek WK Suh MH Jin IN Kwon TK Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells Cancer Lett 2001 163 43 49 11163107 Ragione FD Cucciolla V Borriello A Pietra VD Racioppi L Soldati G Manna C Galletti P Zappia V Resveratrol arrests the cell division cycle at S/G2 phase transition Biochem Biophys Res Commun 1998 250 53 58 9735330 Romagnolo D Annab LA Thompson TE Risinger JI Terry LA Barrett JC Afshari CA Estrogen upregulation of BRCA1 expression with no effect on localization Mol Carcinog 1998 22 102 109 9655254 Soule HD Vazguez J Long A Albert S Brennan M A human cell line from a pleural effusion derived from a breast carcinoma J Natl Cancer Inst 1973 51 1409 1416 4357757 Spillman MA Bowcock AM BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to oestrogen Oncogene 1996 13 1639 1645 8895509 Sun NJ Woo SH Cassady JM Snapka RM DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia J Nat Prod 1998 61 362 366 9544566 Thakur S Zhang HB Peng Y Le H Carroll B Ward T Yao J Farid LM Couch FJ Wilson RB Weber BL Localization of BRCA1 and a splice variant identifies the nuclear localization signal Mol Cell Biol 1997 17 444 452 8972225 Vaughn JP Cirisano FD Huper G Berchuck A Futreal PA Marks JR Iglehart JD Cell cycle control of BRCA2 Cancer Res 1996 56 4590 4594 8840967 Vissac C Antoine-Vincent D Maurizis JC Bignon YJ Bernard-Gallon D Determination of BRCA2 oncosuppressor protein expression in human mammary cells by affinity perfusion high-performance chromatography J Biochem Biophys Methods 2001 49 657 663 11694309 Vissac C Lemery D Le Corre L Fustier P Dechelotte P Maurizis JC Bignon YJ Bernard-Gallon DJ Presence of BRCA1 and BRCA2 proteins in human milk fat globules after delivery Biochim Biophys Acta 2002 1586 50 56 11781149 Wickens M Anderson P Jackson RJ Life and death in the cytoplasm: messages from the 3′ end Curr Opin Genet Dev 1997 7 220 232 9115434 Wilson CA Payton MN Elliott GS Buaas FW Cajulis EE Grosshans D Ramos L Reese DM Slamon DJ Calzone FJ Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b Oncogene 1997 14 1 16 9010228 Xu CF Chambers JA Solomon E Complex regulation of the BRCA1 gene J Biol Chem 1997 272 20994 20997 9261099 Ziche M Gullino PM Angiogenesis and neoplastic progression in vitro J Natl Cancer Inst 1982 69 483 487 6180208